Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
about
Potential approaches to the treatment of Ewing's sarcomaReceptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersNilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomasLack of CD117 and rare bcl-2 expression in stomach cancer by immunohistochemistry. An immunohistochemical study with review of the literature.Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexedABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways.The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cellsPrimary primitive neuroectodermal tumour of the urinary bladder: a clinico-pathological study emphasising immunohistochemical, ultrastructural and molecular analysesTargeted therapy in Ewing sarcoma.Treatment approaches for metastatic Ewing's sarcoma: a review of the literature.Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells.Novel approaches for the management of patients with Ewing sarcoma.Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.Ewing sarcoma: biology-based therapeutic perspectives.Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?Targeted therapies for bone sarcomas.Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.Pericytes in sarcomas of bone.Topics in histopathology of sweat gland and sebaceous neoplasms.miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor.Bone sarcomas: from biology to targeted therapies.Imatinib inhibits inactivation of the ATM/ATR signaling pathway and recovery from adriamycin/doxorubicin-induced DNA damage checkpoint arrest.Immunohistochemistry for CD117 (KIT) is effective in distinguishing cutaneous adnexal tumors with apocrine/eccrine or sebaceous differentiation from other epithelial tumors of the skin.Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone--an array comparative genomic hybridization study.
P2860
Q28072744-5902B97A-051C-4DF9-8B68-833AB8512790Q28082793-33E9BF53-A376-4AA6-9B9A-F00010DAEC4DQ28483929-03A12A35-A2E2-451B-816A-1706296EB61CQ33246030-3DC71EB6-DD3E-4A5D-9B0B-92A006FA7BFCQ33274781-0F81CF37-7082-4A28-9385-26E1876F9558Q33723414-31FC8753-52F8-461E-AB25-F2267941CF81Q35126922-38836378-3DD9-4AC5-B225-5CAB07DB2B3CQ35770117-FF9C4212-D6DF-4C84-86FC-270AE4E6FC57Q36011879-BB0C242C-78F1-4B21-81DA-2B2D0F05D1FAQ36282728-DC80EF98-F1F8-46DA-8B03-7167E9862881Q36498079-81FF1EF6-9CFF-4822-878D-9A9677F21044Q36616528-30B0F5AC-943B-4BBB-9E64-02533FF56DE7Q36974779-172C0C8D-321C-407A-8C44-BE8ED1CE3404Q37301320-61342569-30D5-4D23-8037-574F062DB81BQ37981253-11EFE844-45D2-4F15-BF38-91E78953D6BAQ38129954-43B2C1B4-38D2-4193-903C-753223E7637DQ38178277-F414F1B8-FB8F-42C7-9284-D19DCC98540DQ38243878-F28F1AE6-9146-4463-9C86-2D6493044EB0Q38528174-781975FB-2CD6-4062-87FE-65D5C5421213Q39159820-47945945-FD8F-4C56-A1AD-19C111AC6461Q41051759-6E1760AD-AF22-4E13-9ED8-8277DB9EED2FQ41923624-1592ACC6-F71E-4F6E-ACF9-FDA99715F2D8Q52957653-34BBE29D-8D7E-4EBD-800F-20257A3EB9EDQ53548885-2E50DF51-05E9-4D9F-8099-A74AC9A76F50Q54712822-F6663A29-EB9E-4B0F-A501-938F3630FE9E
P2860
Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Imatinib inhibits proliferatio ...... doxorubicin-induced apoptosis.
@en
type
label
Imatinib inhibits proliferatio ...... doxorubicin-induced apoptosis.
@en
prefLabel
Imatinib inhibits proliferatio ...... doxorubicin-induced apoptosis.
@en
P2093
P50
P1476
Imatinib inhibits proliferatio ...... doxorubicin-induced apoptosis
@en
P2093
Ana Fontalba
Angel Panizo
Iranzu González
Javier Pardo
José Luis Fernández-Luna
Luis Sierrasesúmaga
Mirella Gaboli
Salvador Martín-Algarra
Susana Inogés
P304
P356
10.1158/1078-0432.CCR-0778-03
P407
P577
2004-01-01T00:00:00Z